Epstein Barr Virus, บทบาทในการเกิดโรคติดเชื้อและมะเร็ง
Keywords:
-Abstract
-
Downloads
References
Cohen JI. Esptein - Barr virus infection. New Engl J Med 2000;343:481-92.
ถนอมศรี ศรีชัยกุล. Pathogenesis of malignant lymphoma. ใน โลหิตวิทยาในเวชปฏิบัติ. บรรณาธิการ ธานินทร์ อินทรกำธรชัย. บริษัท บียอนด์เอนเทอร์ไพล์ กรุงเทพ. 2542:299-310.
Risdall RJ, Meckenna RW, Nesbit ME, et al. Virus associated hemophagocytic syndrome, a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979;44:998-1002.
Wong K, Chan J. Reactive hemophagocytic syndrome a clinicopathologic study of 40 patients in oriental population. Amer J Med 1992;93:177.
Imaskuku S, Hibi S. Ohara T, et al. Effective control of EBV-Related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 199999,93:1869-74.
Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998;395:462-9.
Harabuchi Y, Imai S, Wakashima J, et al. Nasal T-cell lymphoma causally associated with Espstein-Barr Virus. Cancer 1996;77:2137-48.
Amore F, Johansen P, Houmand A, et al. Epstein-Barr virus genome in NHL occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T cell lymphoma and correlation with poor prognosis. Blood 1996;87:1045-55.
Mitarnum W. Kietthubthew S, Supapom S. Hepatic peripheral T cell lymphoma: A spectrum of liver pathology and clinical correlation. J Med Ass Thai 1997;80:219-31.
Martines LO, Kumar S, Fend F, et al. Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infections a distinct clinicopathologic syndrome. Blood 2000;96:443-51.
Klein G, Klein E. EBV and human lymphomas in Malignant Lymphoma edited by Conellos GP, Lister TA, Sklar JL, WB Saunder Co 1988:63-73-73.
Nieodobitck G, Agathanggelon A, Rowe M, et al. Heterogenesis expression of EBV latent protein in endemic Burkitt's lymphoma. Blood 1995;86:659-65.
Anwar N, Kingma DW, Block AR, et al. The investigation of EBV sequences in 41 cases of Burkitt's lymphoma from Egypt epidemiologic correlation. Cancer 1995;176:1245-52.
Thomas JA, Crawford DH, Burke M. Clinopathologic implication of Epstein Barr virus related B cell lymphoma in immunocompromised patients. J Clin Pathology 1995;48:287-90.
Wang CY Snow JL. SU-WP Lymphoma associated with human immunodeficiency virus infection. Mayo Clin Proc 1995;70:665-72.
Resnick L, Herbst JS, Ablashi DV, et al. Regression of oral hairy leukoplakia after orally administration acyclovir therapy. JAMA 1988;259:384-8.
Tynell E, Aureline E, Brandell A, et al. Acyclovia and prednisolone treatment of acute infectious mononucleosis. J Infect Dis 1996;174:324-31.
Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:1583-7.
Davis CT, Wood BI, Sabath DF, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorders in recipients of solid organ transplants. Transplantation 1998;66:1770-9.
Milpied N, Antoine C, Garnier JL, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in B post-transplant lymphoproliferative disorders. Am Oncol 1999;10(suppl 3):5.
O' Reilly RJ, Small TN, Papadopoutos E, et al. Biology and adoptive cell therapy of EBV associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997;157:195-216
Pary CV, Fung JJ, Naksnik MA, et al. EBV induced post-transplant lymphoproliferative disorders. Transplantation 1999;68:1517-25.
Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of EBV induced lymphoma in allegencic transplant recipients. Blood 1998;92:1549-55.
Rooney CM, Roskrow MA, Smith CA, et al. Immunotherapy for EBV associated cancers. In: First National AIDS malignancy Conference J of National Cancer Institute monographs No 23. Bethesda MD NCI 199998:89-93.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
